International legal practice Osborne Clarke has advised the majority shareholders of Exploristics Ltd, a global provider of specialised software products and technology-enabled services to the life sciences sector, on its sale to data-focused clinical research organisation (CRO) MMS.
Exploristics' expertise in biostatistics and data science, along with their flagship study simulation product KerusCloud®, will strengthen MMS' strategic capabilities as a leading data-focused CRO and expand its expertise and global reach across Europe.
The Osborne Clarke team advising on this deal consisted of Justin Starling (Partner), Lesley Olsen (Associate Director), Mary Hughes (Senior Associate) and Emma Hooper (Trainee) in the Corporate team; Tracey Wright (Partner) and Anna Reynolds (Senior Associate) in the Tax team; and Michael Carter (Partner), Natalie Paddock (Senior Associate) and Maryam Khalifa (Associate) in the Incentives team.
"We are delighted to have represented Aiden Flynn and other major shareholders in this transaction. This deal is one of many sell-side mandates in the Life Sciences and Healthcare sector that Osborne Clarke has supported, underscoring our extensive experience and expertise in this sector and ability to ensure successful exit outcomes for our clients."
Osborne Clarke’s Corporate team has a strong track record of advising life science and healthcare sector investors and companies on transactions and cutting-edge issues. The team combines extensive market knowledge and deep sector expertise to support companies at every stage of development across all corporate issues, from equity and debt fundraisings to M&A, IPOs and JVs.
